Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5,with follow-up through 1 year at dose selected for Phase 2 Durable ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic fibrosis (CF), which offer a different mechanism to those sold by market ...

Vertex’s quest to treat a wider group of patients with cystic fibrosis (CF) continues after the FDA approved its latest combination therapy, Symdeko. Symdeko adds the new component of tezacaftor to ...

About This EventSionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing ...

Sometimes, a small error in the sequence of DNA can lead to a very serious disease. Scientists have identified many mutations ...